College of Pharmacy, Gulf Medical University, Ajman, UAE.
Thumbay University Hospital, Ajman, UAE.
J Int Med Res. 2021 Oct;49(10):3000605211049943. doi: 10.1177/03000605211049943.
The objective was to compare the efficacy of azithromycin and clarithromycin in combination with beta-lactams to treat community-acquired pneumonia among hospitalized adults.
Five databases (PubMed, Google Scholar, Trip, Medline, and Clinical Key) were searched to identify randomized clinical trials with patients exposed to azithromycin or clarithromycin in combination with a beta-lactam. All articles were critically reviewed for inclusion in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Seven clinical trials were included. The treatment success rate for azithromycin-beta-lactam after 10 to 14 days was 87.55% and that for clarithromycin-beta-lactam after 5 to 7 days of therapy was 75.42%. was commonly found in macrolide groups, with 130 and 80 isolates in the clarithromycin-based and azithromycin-based groups, respectively. The length of hospital stay was an average of 8.45 days for patients receiving a beta-lactam-azithromycin combination and 7.25 days with a beta-lactam-clarithromycin combination.
Macrolide inter-class differences were noted, with a higher clinical success rate for azithromycin-based combinations. However, a shorter length of hospital stay was achieved with a clarithromycin-beta-lactam regimen. Thus, a macrolide combined with a beta-lactam should be chosen using susceptibility data from the treating facility.
比较阿奇霉素和克拉霉素联合β-内酰胺类药物治疗住院成人社区获得性肺炎的疗效。
检索了 5 个数据库(PubMed、Google Scholar、Trip、Medline 和 Clinical Key),以确定暴露于阿奇霉素或克拉霉素联合β-内酰胺类药物的患者的随机临床试验。所有文章均按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行批判性评价,以确定是否纳入。
共纳入 7 项临床试验。阿奇霉素-内酰胺类药物治疗 10-14 天后的治疗成功率为 87.55%,克拉霉素-内酰胺类药物治疗 5-7 天后的治疗成功率为 75.42%。大环内酯类药物组中常发现肺炎链球菌,克拉霉素组和阿奇霉素组分别有 130 株和 80 株。接受β-内酰胺-阿奇霉素联合治疗的患者平均住院时间为 8.45 天,而接受β-内酰胺-克拉霉素联合治疗的患者平均住院时间为 7.25 天。
大环内酯类药物之间存在差异,阿奇霉素联合治疗的临床成功率更高。然而,克拉霉素-内酰胺类药物方案可实现更短的住院时间。因此,应根据治疗机构的药敏数据选择与β-内酰胺类药物联合使用的大环内酯类药物。